Lapatinib-mediated COX-2 expression via EGFR/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells

ASIA unversity > 醫學暨健康學院 > 生物科技學系 > 期刊論文 > Item 310904400/25189

Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/25189

Title:	Lapatinib-mediated COX-2 expression via EGFR/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells
Authors:	Hsia, Te-Chun;Hsia, Te-Chun;Hsia, Te-Chun;Hsia, Te-Chun;Chen, Yun-Ju;Chen, Yun-Ju;Wei, Ya-Ling;Wei, Ya-Ling;Meng-Chieh, Y;Yu, Meng-Chieh;Sheng-Chie, H;Hsu, Sheng-Chie;Shing-Ling, T;Tsai, Shing-Ling;Chen, Wen-Shu;Chen, Wen-Shu;Ming-Hsin, Alex, Yeh,;余永倫;Yu, Yung-luen;Hua, Tzungchi;Huang, Tzungchi;Hu, Chih-Yang;Huang, Chih-Yang;Hu, Mien-Chie;Hung, Mien-Chie
Contributors:	生物科技學系
Date:	2013
Issue Date:	2013-07-11 13:55:00 (UTC+8)
Abstract:	Lapatinib, a dual epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) kinase inhibitor, showed clinical benefits in advanced HER2-positive breast cancer patients. Because some triple-negative breast cancers (TNBCs) frequently overexpress EGFR, the antitumor activity of lapatinib in such diseases was also tested. However, the results showed a worse event-free survival rate. It remains unknown whether and how lapatinib elicits the aggressiveness of such cancer cells. In this study, our results demonstrated that lapatinib facilitated axillary and lung metastases of triple-negative MDA-MB-231 breast cancer cells without affecting their viability, leading to worse survival in orthotopic xenograft mice. The lapatinib-increased motility was attributed by the elevation of EGFR through the downregulation of microRNA-7 and by the subsequent overexpression of cyclooxygenase-2 (COX-2). Strikingly, independent of its kinase activity, the elevated EGFR at least partly stabilized COX-2 expression by enhancing the binding of HuR to COX-2 mRNA. Our results suggest that lapatinib may increase the migration and invasion of MDA-MB-231 cells by upregulating EGFR and COX-2 through the downregulation of microRNA-7, providing a potential explanation for the worse clinical outcome of TNBC patients who receive lapatinib-based treatment. These findings also shed new light on the molecular mechanism of COX-2 mRNA stabilization by EGFR in a kinase-independent manner.
Relation:	MOLECULAR PHARMACOLOGY;83(4):857-69.
Appears in Collections:	[生物科技學系] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	333	View/Open

Loading...